NIH: Fogarty International Center NIH: Fogarty International Center
Advancing Science for Global Health
Advancing Science for Global Health
Home > Research Topics > Malaria Drug Resistance Print

COVID-19: COVID-19 public health information from the US CDC | COVID-19 research information from the US NIH | Español | COVID-19 resources for global health researchers

Malaria Drug Resistance

Close up of hands holding FDA Counterfeit Detection Device-3 CD-3, black electronic box with many buttons emits glow on bottom

Global pandemic of fake medicines poses urgent risk

Poor quality medicines are a real and urgent threat that could undermine decades of successful efforts to combat HIV/AIDS, malaria and tuberculosis, according to the editors of a new collection of journal articles.

More
Close up of four pills in pack scanned using FDA tool, yellow glow, fake pills show white spots indicating irregularities

Poor quality malaria drugs pose threat

Poor quality antimalarial drugs lead to drug resistance and inadequate treatment that pose an urgent threat to vulnerable populations, according to a Fogarty study.

More
close up of white malaria test showing red indicator sitting on top of sheet of paper with title laboratory

Resistance to malaria drugs is a growing concern

Fogarty and NIAID convened drug-resistant malaria experts to examine the problem, identify possible approaches, spark collaborations and spur the field to take action.

More
Man squatting looks through microscope, woman seated prepares samples, both on wooden platform with open air sides

Mutation behind drug-resistant malaria

An international collaboration that includes NIAID uncovered a mutation in the malaria parasite in Cambodia that enables it to survive artemisinin, the most potent antimalarial drug available.

More